VRAD Co. Ltd Launches Two Virtual Reality based Medical Stimulators

VRAD Co. Ltd Launches Two Virtual Reality based Medical Stimulators

Highlights

  • Immersive clinical simulation platform enabling users to perform clinical exercises with simulated patients in a virtual environment

VRAD Co., Ltd. is introducing two Korean-developed virtual reality simulators, NS_Core and IP_Trauma, to global markets. These simulators support various languages, including Korean, English, Vietnamese, Thai, Indonesian, Chinese, Japanese, Kazakh, and German, with Spanish and French set to follow by year-end.

NS_Core is a virtual reality simulation solution designed for nursing skill training using Meta’s headset. It enables users to practice clinical exercises with simulated patients, addressing challenges in hands-on training within nursing school curricula. Developed through collaboration between hospitals and universities, NS_Core allows intensive practice on 20 essential nursing skills to improve clinical performance.

IP_Trauma is a VR training platform aimed at enhancing trauma care skills in medical personnel. It focuses on teaching procedures, equipment use, situational assessment, decision-making, teamwork, and real-time communication. Created in partnership with Korean universities and hospitals, it adheres to globally recognised Advanced Trauma Life Support protocol standards and incorporates reactive scenario simulations.

The IP_Trauma simulator enables real-time communication between users, allowing them to practice trauma care techniques and critical decision-making in a virtual setting. It includes over 40 procedural steps, from pre-hospital preparation to patient transfer. Simulation managers can assign scenarios, give instructions, and guide participants during training.

VRAD, a leading VR medical technology provider in Korea, supplies its products to over 90 institutions worldwide.

Related post

FDA Approves First-of-its-Kind Treatment for Rare Lung Disease in Over a Decade

FDA Approves First-of-its-Kind Treatment for Rare Lung Disease in…

Highlights: Jascayd tablets represents the first-of-its-kind therapy for idiopathic pulmonary fibrosis (IPF) in more than a decade Patients are able to…
Microsoft’s Rural Health Resilience Program Making Waves

Microsoft’s Rural Health Resilience Program Making Waves

Highlights: The losses incurred in denied claims amounts to USD 3,30,000 in the US annually Claim denials navigator is a free-to-use…
AstraZeneca’s DatroWay Delivers Breakthrough in Advanced Breast Cancer Survival

AstraZeneca’s DatroWay Delivers Breakthrough in Advanced Breast Cancer Survival

Highlights: DatroWay, a new innovation by AstraZeneca, boosts survival odds among advanced breast cancer patients DatroWay utilises ADC that delivers high-precision…